Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NSPR - InspireMD, Inc. So'nggi Yangiliklar | Finranks

Home

NSPR

(NSPR)

NCM – Real vaqt narxi. Valyuta: USD

1.59

-0.14 (-8.09%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.60

+0.01 (0.73%)

Bozordan keyin: Mar 27, 2026, 5:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript

InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript

InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript

InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company's MicroNet™ covered stent in patients with asymptomatic carotid stenosis.

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis

Videolar

No Data

There is no data to display

Press-relizlar

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company's MicroNet™ covered stent in patients with asymptomatic carotid stenosis.

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis